Publication Date
1-1-2022
Journal
Cell Transplantation
DOI
10.1177/09636897221119734
PMID
36927092
PMCID
PMC9478732
PubMedCentral® Posted Date
9-14-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Humans, Herpesvirus 6, Human, Antiviral Agents, Graft vs Host Disease, Roseolovirus Infections, Encephalitis, Viral, Hematopoietic Stem Cell Transplantation, human herpesvirus-6, encephalitis, hematopoietic stem cell transplant, amnesia, HHV-6, reactivation
Abstract
A patient with an ultimate diagnosis of human herpesvirus-6 (HHV-6) encephalitis developed central nervous system (CNS) symptoms 13 days after undergoing myeloablative haploidentical allogeneic hematopoietic stem cell transplant (HSCT). Due to the patient's body habitus, magnetic resonance (MR) imaging was not obtained until the onset of retrograde amnesia on day +24. MR imaging and other clinical findings eliminated all skepticism of HHV-6 encephalitis and HHV-6 antivirals were initiated on day +28, leading to gradual recovery. This case demonstrates some of the factors that may complicate the diagnosis of post-alloHSCT HHV-6 encephalitis. Because HHV-6 encephalitis and viremia can occur without warning, a single negative study should not exclude future development, especially if CNS symptoms are present. Acute graft-versus-host disease and cord blood transplantation are both significant risk factors for HHV-6 encephalitis. Human leukocyte antigen (HLA) mismatch, engraftment complications, or certain HLA alleles have also been associated with HHV-6 encephalitis. Chromosomally integrated HHV-6 must also be ruled out to prevent inappropriate and potentially harmful administration of antivirals. Due to the severe short- and long-term sequelae of HHV-6 encephalitis, appropriate treatment should be administered as soon as possible.
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Genetic Processes Commons, Hematology Commons, Hemic and Lymphatic Diseases Commons